耐药结核病分子诊断技术研究进展

中国防痨杂志 ›› 2011, Vol. 33 ›› Issue (9): 608-610.

耐药结核病分子诊断技术研究进展

张军

天津市海河医院

出版日期:2011-09-10 发布日期:2012-01-29

Development of molecular diagnosis of drug resistance tuberculosis

ZHANG Jun

Online:2011-09-10 Published:2012-01-29

摘要/Abstract

张军.
耐药结核病分子诊断技术研究进展[J]. 中国防痨杂志, 2011, 33(9): 608-610.

ZHANG Jun. Development of molecular diagnosis of drug resistance tuberculosis[J]. Chinese Journal of Antituberculosis, 2011, 33(9): 608-610.

［1］Word Health Organization. Guidelines for the programmatic management of drug-resistent tuberculosis. Geneva: WHO, 2006: 5-18.
［2］高官聚, 吴树才, 池跃朋. 耐药结核病的发生发展及控制展望. 河北医药, 2009, 31(10):1246-1248.
［3］唐神结, 肖和平. 严重耐多药结核病的成因与对策［J/CD］. 中华临床医师杂志: 电子版，2009，3(3):62-66 ［2011-01-28］．http:∥www.cqvip.com/Read/Read.aspx?id=29807489.
［4］张丽, 黄汉平, 张茜. 广泛耐药肺结核患者临床分析. 临床医学, 2010, 30(3): 22-24.
［5］World Health Organization．Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008．Geneva: World Health Organization, 2008．
［6］Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med, 2010，181(1): 80-86．
［7］Choi JH, Lee KW, Kang HR, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest, 2010, 137(2): 393-400.
［8］Brown TJ,Herrera-Leon L,Anthony RM,et al. The use of macroarrays for the identification of MDR Mycobacterium tuberculosis. J Microbiol Methods, 2006, 65(2): 294-300.
［9］俞学锋, 钟利. 结核分枝杆菌耐药机制研究进展. 西南军医, 2010, 12(1): 125-127.
［10］吴长东, 袁俐. 耐药结核病的分子生物学研究进展. 中国病原生物学杂志, 2009, 4(12): 943-945.
［11］杨松, 张耀亭. 结核病耐药的分子机制及其防治研究进展. 临床肺科杂志, 2006, 11(5): 632-633.
［12］Morris S, Bai GH, Suffys P, et a1. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis, 1995, 171(4): 954-960.
［13］Kim BJ, Lee KH, Park BN, et a1. Detection of rifampin-resistant Mycobacterium tuberculosis in sputa by nested PCR—linked single-strand conformation polymorphism and DNA sequencing．J Clin Microbiol, 2001, 39(7): 2610-2617.
［14］Abal AT, Ahmad S, Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist, 2002, 8（2）: 99-105.
［15］王巍, 李洪敏, 吴雪琼, 等. 结核分支杆菌五种耐药基因检测的临床应用及评价. 中华结核和呼吸杂志, 2002, 25（11）: 670-673.
［16］Williams DL, Spring L, Gillis TP, et al. Evaluation of polymerase chain reaction-based universal heteroduplex generator assay for direct detection of rifampin susceptibility of Mycobacterium tuberculosis from sputum specimens. Clin Infect Dis, 1998, 26(2): 446-450.
［17］Thomas GA, Williams DL, Soper SA. Capillary electrophoresis-based heteroduplex analysis with a universal heteroduplex generator for detection of point mutations associated with rifampin resistance in tuberculosis. Clin Chem, 2001, 47(7): 1195-1203.
［18］Nachamkin I, Kang C, Weinstein MP. Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Clin Infect Dis, 1997, 24(5): 894-900.
［19］Victor TC, van Helden PD, Warren R. Prediction of drug resistance in M. tuberculosis: molecular mechanisms, tools, and applications. IUBMB Life, 2002, 53(4-5): 231-237.
［20］Makinen J, Marttila HJ, Marjamaki M, et al. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol, 2006, 44(2): 350-352.
［21］Ling DI, Zwerling AA, Pai M. Geno type MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J, 2008, 32（5）: 1165-1174.